Table 3.
Analysis of pre-operative risk factors influencing 5-year mortality.
| Simple regression | Multivariable regression | |||
|---|---|---|---|---|
| Explanatory variable | P-value | HR (95% CI) | P-value | HR (95% CI) |
| Age at diagnosis | 0.052 | 1.01 (1.00–1.02) | 0.015* | 1.01 (1.00–1.03) |
| Unfavorable tumor histology a | 0.025* | 2.49 (1.09–5.68) | 0.043* | 2.39 (1.03–5.54) |
| Tumor in adrenal gland | 0.08 | 2.29 (0.90–5.82) | ||
| Sex | 0.59 | 1.26 (0.55–2.92) | ||
| INSS 4 | 0.16 | 1.96 (0.77–4.96) | ||
| MYCN + | 0.006* | 3.19 (1.39–7.32) | ||
| WFA z | 0.07 | 0.71 (0.49–1.02) | ||
| HFA z | 0.19 | 0.81 (0.59–1.11) | ||
| BMI z | 0.08 | 0.75 (0.54–1.03) | ||
| Sarcopenia | 0.039* | 4.26 (1.00–8.65) | 0.048* | 4.18 (1.01–17.26) |
| NB2004-HR chemotherapyb | 0.020* | 2.77 (1.17–6.54) | 0.046* | 2.46 (1.02–5.92) |
*
Represents a significant result with P <0.05.
a
Includes poorly differentiated neuroblastoma, undifferentiated neuroblastoma, and nodular ganglioneuroblastoma (25).
b
According to GPOH recommendations (29).
BMI, body mass index; CI, confidence interval; HFA, height-for-age; HR, hazard ratio; INSS, International Neuroblastoma Staging System; WFA, weight-for-age; z, z-score.